Vktx nasdaq.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023NASDAQ VKTX. Open. $12.01. Change. $0.69 (5.83%) Day's Range. $12.01 - $12.67. 52-Week Range. $3.54 - $25.72. Volume. 562.4K. Market Cap. $1.3B. Currency in USD. …Clinical-stage biotech Viking Therapeutics ( VKTX 6.23%) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume ...Jun 27, 2023 · Looking at the chart above, VKTX's low point in its 52 week range is $2.5345 per share, with $25.7199 as the 52 week high point — that compares with a last trade of $15.54. Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported third quarter EPS of $-0.230, $0.01 worse than the analyst estimate of $-0.220. Revenue for the quarter came in at... After-Hours Stock Movers: Viking Therapeutics, Inc. (NASDAQ:VKTX) 6% HIGHER; announced that new results from the company's Phase 1 single ascending dose (SAD) …Finally, the Nasdaq Composite is experiencing the worst drop today with a 0.39% decrease this morning. ... Why Is Viking Therapeutics (VKTX) Stock Moving Today? On the date of publication, ...

The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.” ... Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 0.94relation to previous closing price ...About Viking Therapeutics Stock (NASDAQ:VKTX) Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes.

That number of contracts represents approximately 709,400 underlying shares, working out to a sizeable 51.3% of VKTX's average daily trading volume over the past month, of 1.4 million shares.Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares.Get the latest Madrigal Pharmaceuticals Inc (MDGL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week.The stock rose 8.7%, resulting in a US$167m rise in the company's market ...

See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on December 4, 2023.The analyst firm set a price target for $32.00 expecting VKTX to rise to within ...

Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported third quarter EPS of $-0.230, $0.01 worse than the analyst estimate of $-0.220. Revenue for the quarter came in at... After-Hours Stock Movers: Viking Therapeutics, Inc. (NASDAQ:VKTX) 6% HIGHER; announced that new results from the company's Phase 1 single ascending dose (SAD) …Research Viking Therapeutics' (Nasdaq:VKTX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Viking Therapeutics, Inc.Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany Participants. Stephanie Diaz - Manager of Investor Relations. Brian Lian - Viking’s ...Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of $3.50. If an investor was to purchase shares of VKTX stock at the current price ...

Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...Mar. 28, 2023, 08:37 AM. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of ...Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ETCompany ParticipantsStephanie Diaz - Manager of...Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, the firm's shares ...

Apr 10, 2023 · Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of $3.50. If an investor was to purchase shares of VKTX stock at the current price ... Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose ...

Fintel reports that on August 8, 2023, Stifel reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 142.45% Upside. As of August 2 ...Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and …NASDAQ: $115: $15 - $17 7,187,500: Goldman Sachs Cowen & Company: Preclinical biotech developing kinase inhibitors for cancer and genetic diseases. CoLucid Pharmaceuticals Burlington, MA: CLCD ...See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX.Aug 24, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viking Therapeutics Inc (Symbol: VKTX), where a total of 11,518 contracts have traded ... Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported third quarter EPS of $-0.230, $0.01 worse than the analyst estimate of $-0.220. Revenue for the quarter came in at... After-Hours Stock Movers: Viking Therapeutics, Inc. (NASDAQ:VKTX) 6% HIGHER; announced that new results from the company's Phase 1 single ascending dose (SAD) …Jul 10, 2023 · Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...

Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...

Nov 28, 2023 · See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. As of February 3, 2023, the average one-year price target for Viking Therapeutics is $18.70. The forecasts range from a low of $11.11 to a high of $31.50. The average price target represents an ... Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ...Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... צפה בגרף ‎Viking Therapeutics, Inc.‎ בזמן אמת כדי לעקוב אחר תנועת מחיר המניה. תמצא תחזיות שוק, ‎VKTX‎ וחדשות שוק כלכליות.

VKTX Viking Therapeutics Inc Viking Therapeutics to Present at SVB Securities Global Biopharma ConferenceStanding squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. This target puts the upside ...26 jul 2023 ... PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of ...Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares.Instagram:https://instagram. boa private bankingtesla brake systemtbil stock dividendfutures trading vs options The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on December 4, 2023.The analyst firm set a price target for $32.00 expecting VKTX to rise to within ... devon stockslowest mortgage rates in tennessee View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... xpp stock Fintel reports that on April 25, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 29.59% Upside. As of ...צפה בגרף ‎Viking Therapeutics, Inc.‎ בזמן אמת כדי לעקוב אחר תנועת מחיר המניה. תמצא תחזיות שוק, ‎VKTX‎ וחדשות שוק כלכליות.A high-level overview of Viking Therapeutics, Inc. (VKTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.